Jantus Lewintre, E.; Sirera Pérez, R.; Cabrera, A.; Blasco, A.; Caballero, C.; Iranzo, V.; Rosell, R.... (2011). Analysis of the prognostic value of soluble epidermal growth factor receptor plasma concentration in advanced non-small-cell lung cancer patients. Clinical Lung Cancer. 12(5):320-327. https://doi.org/10.1016/j.cllc.2011.03.031
Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/65056
Título:
|
Analysis of the prognostic value of soluble epidermal growth factor receptor plasma concentration in advanced non-small-cell lung cancer patients
|
Autor:
|
Jantus Lewintre, Eloisa
Sirera Pérez, Rafael
Cabrera, Andrea
Blasco, Ana
Caballero, Cristina
Iranzo, Vega
Rosell, Rafael
Camps, Carlos
|
Entidad UPV:
|
Universitat Politècnica de València. Departamento de Biotecnología - Departament de Biotecnologia
|
Fecha difusión:
|
|
Resumen:
|
[EN] Background: Epidermal growth factor receptor (EGFR) is overexpressed in a variety of epithelial malignancies including lung cancer. A soluble fragment of the EGFR extracellular domain (sEGFR) can be detected in the ...[+]
[EN] Background: Epidermal growth factor receptor (EGFR) is overexpressed in a variety of epithelial malignancies including lung cancer. A soluble fragment of the EGFR extracellular domain (sEGFR) can be detected in the blood of patients who have Non-small-cell lung cancer (NSCLC), but its clinical/ prognostic role must be further elucidated. Methods: sEGFR concentration was retrospectively determined by enzyme-linked immunosorbent assay in plasma samples from 308 advanced NSCLC patients (before treatment) and 109 healthy controls and correlated with clinico-pathological variables. Results: The concentration of sEGFR was lower in NSCLC patients than in controls (P <.0001). sEGFR behaves as a sensitive but not specific screening biomarker. No significant associations were observed between sEGFR concentration and demographic/clinical characteristics such as gender, Eastern Cooperative Oncology Group performance status, stage, and number or location of the metastatic sites. sEGFR was lower in patients with progressive disease or in squamous cell carcinoma compared with adenocarcinoma, but these differences were not significant. Patients with sEGFR ¿ 34.56 ng/mL showed a shorter overall survival (median 9.1 versus 12.2 months, P =.019) than others. Moreover, in multivariate analysis, sEGFR remained a significant independent prognostic marker. Conclusion: Low baseline sEGFR is associated with reduced survival in advanced NSCLC. Therefore, our findings in this large cohort of patients suggest that the determination of sEGFR concentration provides valuable prognostic information. © 2011 Elsevier Inc. All rights reserved.
[-]
|
Palabras clave:
|
Biomarker
,
EGFR prognostic
,
NSCLC
,
Cisplatin
,
Docetaxel
,
Epidermal growth factor receptor
,
Erlotinib
,
Gefitinib
,
Adult
,
Advanced cancer
,
Aged
,
Article
,
Cancer combination chemotherapy
,
Cancer growth
,
Cancer localization
,
Cancer patient
,
Cancer survival
,
Cohort analysis
,
Controlled study
,
Disease course
,
Disease severity
,
Distant metastasis
,
Enzyme linked immunosorbent assay
,
Female
,
Functional status
,
Gender
,
Human
,
Human tissue
,
Large cell carcinoma
,
Lung adenocarcinoma
,
Lung metastasis
,
Lung non small cell cancer
,
Lung squamous cell carcinoma
,
Major clinical study
,
Male
,
Multiple cycle treatment
,
Overall survival
,
Prognosis
,
Protein blood level
,
Receiver operating characteristic
,
Retrospective study
,
Sensitivity and specificity
,
Survival time
,
Adenocarcinoma
,
Aged, 80 and over
,
Carcinoma, Non-Small-Cell Lung
,
Carcinoma, Squamous Cell
,
Case-Control Studies
,
Disease Progression
,
Enzyme-Linked Immunosorbent Assay
,
Humans
,
Lung Neoplasms
,
Middle Aged
,
Multivariate Analysis
,
Receptor, Epidermal Growth Factor
,
Retrospective Studies
,
Survival Rate
,
Tumor Markers, Biological
|
Derechos de uso:
|
Cerrado |
Fuente:
|
Clinical Lung Cancer. (issn:
1525-7304
)
|
DOI:
|
10.1016/j.cllc.2011.03.031
|
Editorial:
|
Elsevier
|
Versión del editor:
|
https://dx.doi.org/10.1016/j.cllc.2011.03.031
|
Código del Proyecto:
|
info:eu-repo/grantAgreement/MSC//RD06%2F0020%2F1024/ES/RED TEMÁTICA DE INVESTIGACIÓN COOPERATIVA DEL CANCER/
European Regional Development Fund (ERDF) "Una manera de hacer Europa"
|
Agradecimientos:
|
This work was sponsored in part by a grant from the Spanish Society of Medical Oncology (SEOM) and by a grant (RD06/0020/1024) from Red Tematica de Investigacion Cooperativa en Cancer (RTICC), Instituto de Salud Carlos III ...[+]
This work was sponsored in part by a grant from the Spanish Society of Medical Oncology (SEOM) and by a grant (RD06/0020/1024) from Red Tematica de Investigacion Cooperativa en Cancer (RTICC), Instituto de Salud Carlos III (ISCIII), the Spanish Ministry of Science and Innovation and the European Regional Development Fund (ERDF) "Una manera de hacer Europa." The authors declare no conflicts of interest or any financial disclosure.
[-]
|
Tipo:
|
Artículo
|